Evidence map›Paper›PMID 1909431›Full record

ArticleNucleic acids research1991

Functional modularity in the SP6 kappa promoter.

E Högbom, A C Magnusson, T Leanderson

Open access · greenAbstract read
In one paragraph

Article in Nucleic acids research, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 19 citations in OpenAlex.

  1. IMGTVaccines · 2022
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

E HögbomImmunology Unit, Lund University, Sweden.
A C Magnusson
T Leanderson
Lund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The requirements of the SP6 kappa promoter for transcriptional activation were studied in nontransformed murine B lymphocytes stimulated with lipopolysaccharide. Three different DNA motifs, besides the TATA-box, were needed for restoration of transcriptional activation to the same magnitude as seen with the native SP6 kappa promoter. The decamer motif (TNCTTTGCAT) was found to induce transcription alone and point-mutation of this element reduced transcription to negligible levels, although the other two required elements were present. The penta-decamer element (TGCAG/CCTGTGNCCAG) did not stimulate transcription alone, but activated transcription synergistically in conjunction with the decamer motif. This synergism required the presence of a third pyrimidine rich element (CCCT) in the decamer 3' flanking sequence. The pyrimidine rich element could partly be substituted for by an E-box core motif (CANNTG) 3' of, but not by the kappa Y motif (CTTCCTTA) 5' of, the decamer. Proteins interacting specifically with the penta-decamer element were detected by band-shift assay. The decamer 3' flanking sequence of the SP6 kappa promoter was found to modify the binding of endogenous Oct2 isoforms to the decamer motif i B lymphocytes, but not in CHO cells transfected with various Oct2 isoforms. Thus, complex protein/DNA interactions can be observed in the SP6 kappa promoter which correlate functionally with a synergism in transcriptional activation.

Indexed as

DNA-Binding ProteinsTranscription, GeneticAnimalsBase SequenceB-LymphocytesCells, CulturedImmunoglobulin Heavy ChainsImmunoglobulin kappa-ChainsMiceMice, Inbred CBAMolecular Sequence DataMutationOctamer Transcription Factor-2Promoter Regions, GeneticTranscription FactorsTransfectionDNA-Binding ProteinsImmunoglobulin Heavy ChainsImmunoglobulin kappa-ChainsOctamer Transcription Factor-2Pou2f2 protein, mouseTranscription Factors

Identifiers

PMID1909431
PMCPMC328619
OpenAlexW1972352934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.